Insider filing · ZBIO

Jason Raleigh Nunn bought $1.2M of Zenas BioPharma (ZBIO)

Executed Oct 9 2025, disclosed Oct 14 2025, 5 days later.

Over the 21 trading sessions from the disclosed entry session (Oct 14 2025), the stock returned +35.5% (delay-adjusted); from the execution session (Oct 9 2025), +23.8%. Derived: entry at the session's open, exit at the close 20 sessions later.

JN Jason Raleigh Nunn Director profile →

Jason Raleigh Nunn (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Zenas BioPharma, Inc. (ZBIO). Across 1 priced purchase filing, the average 21-session return was +23.8% from execution and +35.5% from disclosure (delay-adjusted; derived). The largest single filing was $1.2M of ZBIO (63,158 sh × $19.00, as filed), executed Oct 9 2025.

ZBIO Zenas BioPharma, Inc. ZBIO · Healthcare · 18 filings in 24 months ticker →

Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→